Iberostar hotel Montenegro, Bečići, Budva, Montenegro October, 7 – 9, 2021 5 th AROME – MONTENEGRO COURSE Bridge between Science and Clinics in Oncology 4 th AROME ESO Joint Consensus Conference Association of Radiotherapy and Oncology of the Mediterranean Area
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Iberostar hotel Montenegro, Bečići, Budva, MontenegroOctober, 7 – 9, 2021
5th AROME – MONTENEGRO COURSEBridge between Science and Clinics in Oncology
4th AROME ESO Joint Consensus Conference
Association ofRadiotherapy and Oncologyof the Mediterranean Area
ZAPOČNITE SADADA PRODUŽITEPREŽIVLJAVANJE1,2,3,4
NEXAVAR® (sorafenib)
NAZIV LIJEKA: Nexavar®, sorafenib, 200 mg, film tableteNOSILAC DOZVOLE: Evropa Lek Pharma d.o.o., Telefon: +382 (0) 77 272 735, Kritskog odreda 4/1, 81000 Podgorica, Crna Gora, BROJ DOZVOLE ZA STAVLJANJE LIJEKA U PROMET: 2030/10/2 - 3246 DATUM PRVE DOZVOLE/OBNOVE DOZVOLE ZA STAVLJANJE LIJEKA U PROMET: 26.02.2010.
PP
-NE
X-M
E-0
008-
1
Za odgovarajuće pacijente sa inoperabilnim hepatocelularnim karcinomom
Reference:1. Llovet JM, Ricci S, Mazzaferro V, et al; for the SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390;2. Cheng AL, Kang ZK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-34;3. Bruix J, Qin S, Merle P, et al; on behalf of the RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebocontrolled, phase 3 trial [published online December 5, 2016]. Lancet. 2016. doi: 10.1016/S0140-6736(16)32453-9; 5. STIVARGA (regorafenib) sažetak opisa svojstava lijeka 09/2019.4. Nexavar®, 200 mg, film tablete, Sažetak karakteristika lijeka, septembar 2020.
Samo za stručnu javnost.
ZAPOČNITE SADADA PRODUŽITEPREŽIVLJAVANJE1,2,3,4
NEXAVAR® (sorafenib)
NAZIV LIJEKA: Nexavar®, sorafenib, 200 mg, film tableteNOSILAC DOZVOLE: Evropa Lek Pharma d.o.o., Telefon: +382 (0) 77 272 735, Kritskog odreda 4/1, 81000 Podgorica, Crna Gora, BROJ DOZVOLE ZA STAVLJANJE LIJEKA U PROMET: 2030/10/2 - 3246 DATUM PRVE DOZVOLE/OBNOVE DOZVOLE ZA STAVLJANJE LIJEKA U PROMET: 26.02.2010.
PP
-NE
X-M
E-0
008-
1
Za odgovarajuće pacijente sa inoperabilnim hepatocelularnim karcinomom
Reference:1. Llovet JM, Ricci S, Mazzaferro V, et al; for the SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390;2. Cheng AL, Kang ZK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-34;3. Bruix J, Qin S, Merle P, et al; on behalf of the RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebocontrolled, phase 3 trial [published online December 5, 2016]. Lancet. 2016. doi: 10.1016/S0140-6736(16)32453-9; 5. STIVARGA (regorafenib) sažetak opisa svojstava lijeka 09/2019.4. Nexavar®, 200 mg, film tablete, Sažetak karakteristika lijeka, septembar 2020.
Samo za stručnu javnost.
ZAPOČNITE SADADA PRODUŽITEPREŽIVLJAVANJE1,2,3,4
NEXAVAR® (sorafenib)
NAZIV LIJEKA: Nexavar®, sorafenib, 200 mg, film tableteNOSILAC DOZVOLE: Evropa Lek Pharma d.o.o., Telefon: +382 (0) 77 272 735, Kritskog odreda 4/1, 81000 Podgorica, Crna Gora, BROJ DOZVOLE ZA STAVLJANJE LIJEKA U PROMET: 2030/10/2 - 3246 DATUM PRVE DOZVOLE/OBNOVE DOZVOLE ZA STAVLJANJE LIJEKA U PROMET: 26.02.2010.
PP
-NE
X-M
E-0
008-
1
Za odgovarajuće pacijente sa inoperabilnim hepatocelularnim karcinomom
Reference:1. Llovet JM, Ricci S, Mazzaferro V, et al; for the SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390;2. Cheng AL, Kang ZK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-34;3. Bruix J, Qin S, Merle P, et al; on behalf of the RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebocontrolled, phase 3 trial [published online December 5, 2016]. Lancet. 2016. doi: 10.1016/S0140-6736(16)32453-9; 5. STIVARGA (regorafenib) sažetak opisa svojstava lijeka 09/2019.4. Nexavar®, 200 mg, film tablete, Sažetak karakteristika lijeka, septembar 2020.
Samo za stručnu javnost.
7th to 9th October 2021, Budva, Montenegro
5th AROME – MONTENEGRO COURSEBridge between Science and Clinics in Oncology
4th AROME ESO Joint Consensus Conference
PRESIDENCY:
Vladimir TODOROVIC (Meeting President)Institute for Oncology, Clinical Center of Montenegro, University of Montenegro,
Podgorica, Montenegro
Joseph GLIGOROV (AROME former President)Institut Universitaire de Cancérologie APHP-Sorbonne Université, Paris, France
Matti AAPRO (ESO executive board member)Clinique du Génolier, Génolier, Switzerland
SCIENTIFIC COMMITTEE:
M Aapro (Switzerland), Y Belkacemi (France), J Gligorov (France), N Pavlidis (Greece), V. Todorovic (Montenegro), P Tsoutsou (Greece).
FACULTY:
M Aapro (Switzerland), O Arsovski (Bosna & Hercegovina), Y Belkacemi (France), A Benider (Morocco), S Beslija (Bosnia & Hercegovina), A Bounedjar (Algeria), H.
Boussen (Tunisia), T Ceric (Bosnia & Hercegovina), N Crnogorac (Montenegro), N Dedic-Plavetic (Croatia), I Djan (Serbia), Z Dzamic (Serbia), A Eniu (Romania), H
Errihani (Morocco), F Geara (Lebanon), J Gligorov (France), Z Gojkovic (Bosnia & Hercegovina), A Id Baih (France), A Janjic (Serbia), R Jankovic (Serbia), K Kerrou
(France), V Kovcin (Serbia), J Lakicevic (Montenegro), I Markovic (Serbia), N Mijalkovic (Serbia), M Moran (USA), N Milasevic (Montenegro), K Mokhtari (France),
G Mustacchi (Italy), M Ozsahin (Switzerland), A Pasic (Bosnia & Herzegovina), N Pavlidis (Greece), L Popovic (Serbia), D Radosavljevic (Serbia), N Radosevic
(France), S Radulovic (Serbia), M Risteski (North Macedonia), Lj Stamatovic (Serbia), T Stantic (Serbia), S Stojanovic (Serbia), I Stojkovski (North Macedonia), I Takac
(Slovenia), V Todorovic (Montenegro), Z Tomasevic (Serbia), Z Tomasevic (Serbia), P Tsoutsou (Switzerland), S Turkan (Turkey), N Vasev (North Macedonia), D Vrbanec
(Croatia), F Vukmirovic (Montenegro) M Zdralevic (Montenegro).
MEETING ORGANIZATION AND REGISTRATION CONTACT:
Novi ASTAKOS Travel & Events e-mail: [email protected] www.astakos.com/arome
THURSDAY 7th OCTOBER 2021
Opening session – Hall A
13.00–14.15 Registration and welcome coffee
14.15–14.30 AROME-ESO course, past, present and future Vladimir Todorovic & Joseph Gligorov
14.30–15.00 COVID-19 & cancer care challenges in emerging countries Yazid Belkacemi (France)
Session 1: Innovations in diagnostics and locoregional treatments – Hall A
18.30–19.00 Primary CNS malignant tumors Karima Mokhtari & Ahmed Id Baih (France)
19.00–20.00 Education sponsored session – Hall A ROCHE
Fusing data with experience in hepatocellular carcinoma
Moderator: Vladimir Todorović
19.00–19.05 Unprecedented unmet need – Vladimir Todorović
19.05–19.20 Brave achievement with IMbrave150 – Davorin Radosavljević
19.20–19.30 Whats the latest advice? – Nenad Mijalković
By putting lives first, we’ve created a legacy that lastsFor 130 years, we have tackled some of the world’s biggest health challenges and provided hope in the fight against disease, for both people and animals. Today, we continue our commitment to be the premier research-intensive biopharmaceutical company in pursuit of medical breakthroughs that benefit patients and society for today, tomorrow and generations to come.
Glosarij d.o.o.Vojislavljevića 76, 81 000 Podgorica,Crna Gora
By putting lives first, we’ve created a legacy that lastsFor 130 years, we have tackled some of the world’s biggest health challenges and provided hope in the fight against disease, for both people and animals. Today, we continue our commitment to be the premier research-intensive biopharmaceutical company in pursuit of medical breakthroughs that benefit patients and society for today, tomorrow and generations to come.
Glosarij d.o.o.Vojislavljevića 76, 81 000 Podgorica,Crna Gora
19.30–19.55 Futures promise: MDT dialogue – Petar Popovič, Gašper Boltežar
19.55–20.00 Conclusion – Vladimir Todorović
19.00–20.00 Education sponsored session – Hall B PFIZER
Treatment guidelines for hormone positive breast cancer – Nada Cicmil
Endocrine therapy for metastatic breast cancer in COVID 19 era (treatment priorities) – Jadranka Lakicević
Palbociclib – from clinical trials to clinical practice – RWD Oncology Institute, Clinical Center of Montenegro – Sanja Lekić
21.00 Gala Dinner SPONSORED BY MSD / GLOSARIJ CD
SATURDAY 9TH OCTOBER 2021
Special Educational Lectures of challenges in emerging countries – Hall A
Chairs: Yazid Belkacemi (France), Paula Tsoutsou (Greece)
09.00–09.30 Challenges on cancer education in emerging countries: ESO experience Alexander Eniu (Romania)
09.30–09.50 Recent advances on CUP Nicolaos Pavlidis (Greece)
09.50–10.30 Coffee Break
AROME-ESO JOINT CONSENSUS CONFERENCE – HALL A
Prioritizing Strategies for Access to Cancer Care and Innovations in Emerging Countries
Joseph Gligorov (France), Vladimir Todorovic (Montenegro), Matti Aapro (Switzerland), Nicolaos Pavlidis (Greece)
10.30–12.30 Expert discussion and voting session
12.30–12.45 Closing remarks
Who we are. What we do. Why we come to work each day?
We believe it’s urgent to deliver medical solutions right now – even as we develop innovationsfor the future. That is why we come to work each day. We commit ourselves to scientific rigor,unassailable ethics, and access to medical innovations for all.
We have been committed to improving lives since the company was founded in 1896 in Basel,Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millionsof patients globally.
We are the world’s number 1 in biotech with 17 biopharmaceuticals on the market. Over half ofthe compounds in our product pipeline are biopharmaceuticals, enabling us to deliver better-targeted therapies.
We are global leader in cancer treatments. We have been at the forefront of cancer researchand treatment for over 50 years, with medicines for breast, skin, colon, ovarian, lung and numerousother cancers.
We invest around 9 billion Swiss francs in Research and Development every year becauseinnovation is our lifeblood. This is amongst the highest Research and Development spends inthe world across all industries.
We are proud of who we are, what we do, and how we do it. We are many, working as one across functions, across companies, and across the world.
Roche celebrate life:125 years of recognizing life as the most precious gift
On 1 October 2021, Roche turns 125 years old!
There seems to be an inherent human desire to push the boundaries of life. In the space of only125 years, the average life expectancy has more than doubled. This was only possible throughthe deliberate nurturing of scientific curiosity and innovation.
But it’s not about the numbers. It’s an investment in moments.
More days, months, years of life. More moments to cherish. More hopes and dreams to inspirethe future. More reasons to celebrate. Because life, at its core, is about celebration – whethercreating new memories or savoring moments of our past. Who we are today at Roche is anaccumulation of millions of moments experienced by many thousands of individuals acrossseveral generations.
This has been the driving force behind our work for 125 years, and this is what will spark themoments of eureka that will propel science forward for the next 125.